Chemgenex gets milestone from Vernalis
Wednesday, 23 February, 2005
Chemgenex Pharmaceuticals (ASX:CXS) will receive a AUD$720,000 milestone payment from its partner Vernalis for progress made on its depression and anxiety target discovery program.
The companies entered into a partnership agreement in August last year, which is worth as much as $2 million in the first year depending on the achievement of milestones, and are working on a further licensing and collaboration agreement. To date, the company has identified ten novel genes and proteins associated with depression and anxiety.
TGA approves donanemab for treatment of early Alzheimer's
The TGA has approved the first amyloid-targeting therapy for people with Alzheimer's in...
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
